^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Final Results of a Phase 1/2 Study of SYK Inhibitor Entospletinib in Combination with Obinutuzumab in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Published date:
11/04/2021
Excerpt:
Efficacy of entospletinib+obinutuzumab was analyzed in the 21 patients with CLL, of which 17 received entospletinib at RP2D (400 mg twice daily). Patients with CLL had a median age of 66 years. Thirteen patients (62%) had TP53 aberration (n=9), complex karyotype (n=6), or NOTCH1 or SF3B1 mutation..Among the 21 efficacy-evaluable participants with CLL, the ORR was 67% (95%CI, 43–85%). Three patients (14%, 95%CI 3–36%) achieved a CR, and 11 patients (53%) had a partial response (PR)...Thus, the combination of entospletinib and obinutuzumab shows an acceptable safety profile.
DOI:
10.1182/blood-2021-146348